How the Mighty Have Fallen: United, Centene, and Novo Nordisk Struggle 8-2-25 - Becker Private Equity & Business Podcast

Summary3 min read

Becker Private Equity & Business Podcast: "How the Mighty Have Fallen: United, Centene, and Novo Nordisk Struggle" Summary

Host: Scott Becker
Release Date: August 2, 2025

Introduction

In the episode titled "How the Mighty Have Fallen: United, Centene, and Novo Nordisk Struggle," Scott Becker delves into the recent downturns of three major players in the healthcare and pharmaceutical industries: UnitedHealthcare, Centene, and Novo Nordisk. He explores the factors contributing to their significant stock declines over the past year and draws broader lessons on maintaining leadership in dynamic markets.

Overview of Recent Performance

Stock Performance Decline:

Centene: Down nearly 66% over the last 52 weeks.
Novo Nordisk: Decreased by 63% in the same period.
UnitedHealthcare: Fell by 58%, marking a substantial drop for what was once considered a stalwart in the industry.

Quote:
"Centene is down almost 66%, Novo Nordisk is now down 63% over the last 52 weeks. And finally, United Healthcare, the behemoth of all behemoths, the strongest of the strong, is down 58% over the last 52 weeks." [01:15]

Historical Success and Current Struggles

UnitedHealthcare:

Previously viewed as a "buy and hold" stock, a cornerstone for long-term portfolios.
Known for being the largest and strongest healthcare insurance company with extensive growth through Optum and a robust provider network.

Quote:
"If you would have asked me just a couple of years ago about these three companies, I would have told you UnitedHealthcare was a buy and hold stock that you want to have in your portfolio forever." [02:45]

Centene:

Dominates the managed Medicare and Medicaid plans market.
Investments driven by its leadership in specific, controlled market segments.

Quote:
"When I look at Centene, I would have made that bet because it's in a very specific market, largely the Medicaid managed care market." [03:10]

Novo Nordisk:

Experienced rapid value appreciation due to the success of GLP1s and weight loss drugs.
The sustainability of its excess profits is now in question.

Quote:
"Novo Nordisk is one of these companies that popped up in value, incredible value, based on their GLP1, the weight loss drugs they've been selling." [04:00]

Analysis of Decline

Becker examines the reasons behind the sharp declines:

Market Saturation and Competition:
- Increased competition in healthcare insurance and pharmaceutical sectors may have eroded market shares.
Sustainability of Growth Drivers:
- Reliance on specific products or services, such as GLP1s for Novo Nordisk, can lead to volatility if those products face market challenges or regulatory changes.
Operational Challenges:
- Maintaining leadership requires continuous innovation and adaptation, which can be resource-intensive and complex.
Economic and Regulatory Pressures:
- Fluctuating economic conditions and changing healthcare regulations may have adversely impacted profitability and growth prospects.

Quote:
"When something's making excess profits, it's not often that it's sustainable for the long run." [05:20]

Lessons Learned

Leadership is Transient:
- Maintaining a top position in the market is increasingly difficult due to evolving industry dynamics.
- Continuous effort and strategic adaptation are essential to sustain leadership.
Investment Risks:
- Even companies with strong past performance can face significant downturns.
- Diversification and cautious investment strategies are important to mitigate risks associated with market volatility.

Quote:
"One of the lessons is it is hard to stay a leader all the time and constantly. And the amount of things you have to do to keep winning in the world of commerce is incredibly challenging." [06:30]

Market Dependency:
- Companies heavily reliant on specific markets or products must be wary of changes that could disrupt their growth trajectories.

Quote:
"You don't know in the long run what's going to happen with that market." [07:00]

Conclusion

Scott Becker underscores the unpredictability of the business landscape, highlighting that even the most formidable companies are not immune to challenges. The episode serves as a cautionary tale for investors and business leaders alike, emphasizing the need for adaptability, diversification, and a keen awareness of market dynamics to navigate the complexities of maintaining long-term success.

Final Quote:
"How the mighty have fallen. United, Centene, and Novo Nordisk. All taken to the chin and plenty of other companies like that." [08:15]

Thank you for listening to the Becker Business Podcast and Becker Private Equity Podcast.

Loading summary

Transcript1 lines

[00:00]
A
This is Scott Becker with the Becker Business Podcast, the Becker Private Equity Podcast. Today's discussion is how the mighty have fallen. UnitedHealthcare, Centene and Novo Nordisk. So here's what's going on. Over the last few years, United, Centene and Nordisk have each hit out of the park. Novo Nordisk on the GLP1s and the weight loss drugs they've been selling. UnitedHealthcare being the biggest and the strongest of the healthcare insurance companies, together with the growth of the provider network and then through Optum and then Centene, which is the absolute leader out there in terms of managed Medicare and managed Medicaid plans. They've just, all three of them have just knocked it out of the box the last several years. So that is very different this year over the last 52 weeks. Let me give you a quick update. Centene is down almost 66%. Novo Nordisk is now down 63% over the last 52 weeks. And finally, United Healthcare, the behemoth of all behemoths, the strongest of the strong, is down 58% over the last 52 weeks. So at the end of the day, we look at this. How the mighty have fallen. There are so many lessons here, but one of the lessons is it is hard to stay a leader all the time and constantly. And the amount of things you have to do to keep winning in the world of commerce is incredibly challenging. If you would have asked me just a couple of years ago about these three companies, I would have told you UnitedHealthcare was a buy and hold stock that you want to have in your portfolio forever. And that might still be the case, but it sure is struggling. Last 52 weeks. Second, when I look at Centene, I would have made that bet because it's in a very specific market, largely the Medicaid managed care market. You don't know in the long run what's going to happen with that market market. But also it might have been something to bet on. Novo Nordisk is one of these companies that popped up in value, incredible value, based on their GLP1, the weight govi and the weight loss drugs. So I don't know if I would have bet on that forever as well, because when something's making excess profits, it's not often that it's sustainable for the long run. But in any event, those are three companies. How the mighty have fallen. United, Centene and Novo Nordisk. All taken to the chin and plenty of other companies like that. Thank you for listening to the Becker Business Podcast and Becker Private Equity podcast. Thank you very, very much.